Kiora Pharmaceuticals (NASDAQ:KPRX) Announces Earnings Results, Beats Estimates By $0.10 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) posted its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.10, FiscalAI reports. The business had revenue of $1.00 million for the quarter.

Kiora Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ KPRX traded down $0.02 during midday trading on Thursday, hitting $1.33. The stock had a trading volume of 20,641 shares, compared to its average volume of 64,861. The business’s 50 day moving average is $2.31 and its 200-day moving average is $2.38. Kiora Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $2.91.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, October 12th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Kiora Pharmaceuticals has an average rating of “Sell”.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.